Prevention and management of immune-related adverse events for biliary tract cancers

Prevention and management of immune-related adverse events for biliary tract cancers

Immune checkpoint inhibitors (ICIs) combined with chemotherapy has become the first-line standard treatment for advanced biliary tract cancers (BTC). However, the application of ICIs comes with its risks of immune-related adverse events (irAEs). BTC patients often face greater challenges in the diag...

Full description

Saved in:

Bibliographic Details
Main Author:	LIU Kun, GUO Wei
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of Surgery Concepts & Practice 2025-03-01
Series:	Waike lilun yu shijian
Subjects:	\|biliary tract cancer(btc)\|immunotherapy\|immune checkpoint inhibitor(ici)\|immune-related adverse event(irae)
Online Access:	https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1751876439817-1105793041.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature
by: Jiaxiang Ji, et al.
Published: (2024-12-01)

Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment
by: John Storwick, et al.
Published: (2025-07-01)

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade
by: Nina B. Curkovic, et al.
Published: (2025-12-01)

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
by: Chen Li, et al.
Published: (2025-05-01)

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy
by: Tatsushi Kawada, et al.
Published: (2025-07-01)

The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
by: Tianhang Zhang, et al.
Published: (2024-12-01)

Immune Checkpoint Inhibitor-Related Sjögren’s Syndrome: An Ocular Immune-Related Adverse Event
by: Hideki Fukuoka, et al.
Published: (2025-05-01)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024-07-01)

Case Report: Laser speckle flowgraphy in a patient with uveitis due to immune-related adverse events by immune checkpoint inhibitors
by: Satoru Kase, et al.
Published: (2025-05-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer
by: Yuefeng Hu, et al.
Published: (2025-12-01)

Clinical characteristic analysis of immune checkpoint inhibitor-related pituitary adverse events
by: Yufan ZHENG, et al.
Published: (2025-08-01)

Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
by: Harun Muğlu, et al.
Published: (2025-02-01)

Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study
by: Yujuan Wu, et al.
Published: (2025-07-01)

Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
by: Jiayi Gao, et al.
Published: (2025-02-01)

Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
by: Klajdi Begaj, et al.
Published: (2025-06-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)
by: Clémence M. C. Huigen, et al.
Published: (2025-08-01)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01)

Hepatotoxicity induced by immune checkpoint inhibitors
by: Flaviu Muresan, et al.
Published: (2024-10-01)

Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis
by: Zhihui Yang, et al.
Published: (2025-03-01)

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
by: Nora Möhn, et al.
Published: (2025-12-01)

Neuroimaging features of immune-related adverse events due to immune checkpoint inhibitor therapy
by: Arian Lasocki, et al.
Published: (2025-06-01)

Spontaneous haematoma: A unique immune-related adverse event alongside other cutaneous reactions in a patient treated with pembrolizumab for metastatic melanoma
by: Dalila Malek, et al.
Published: (2024-12-01)

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review
by: Kevin Y. Wu, et al.
Published: (2024-11-01)

Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis
by: Qimei Fang, et al.
Published: (2025-02-01)

Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database
by: Huiping Zhang, et al.
Published: (2025-08-01)

A systematic review of gastritis as an immune-related adverse event in clinical interventions
by: Fei Su, et al.
Published: (2024-12-01)

Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
by: Jürgen Braun, et al.
Published: (2024-11-01)

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
by: Xiaomeng Di, et al.
Published: (2025-07-01)

Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma
by: QI Zhong, CHENG Shi
Published: (2025-03-01)

Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database
by: Huiping Zhang, et al.
Published: (2025-04-01)

Moderate toxicity with late onset as a good omen: association between toxicity and survival in the checkpoint inhibitor immunotherapy—a single center experience
by: Anna Rudzińska, et al.
Published: (2025-04-01)

Construction of predictive model for programmed death-1 inhibitor-related endocrine adverse events
by: Jiaying SHI, et al.
Published: (2025-08-01)

Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events
by: Khashayar Esfahani, et al.
Published: (2025-02-01)

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
by: Qing Zhang, et al.
Published: (2025-04-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)